In May 2023, Nature published on the progress of a participant from a 2021 clinical feasibility study in which the Companys ARC-IM\xae Therapy was paired with an implanted brain-computer interface (BCI) for the first time, resulting in that individual gaining augmented control over when and how he moved his paralyzed legs. Also in May 2023, the Company completed the successful first-in-human use of the ARC-IM Lead, designed to deliver ARC Therapy to areas of the spinal cord responsible for a specific function, such as mobility or blood pressure regulation. This additional research site prepares the Company for expected Q4 2024 initiation of a global pivotal trial called Empower BP to assess the safety and efficacy of ARC-IM Therapy to improve blood pressure regulation. Based on positive feedback from potential customers on the value of the ARC-EX System, now demonstrated to be the first-ever therapy to restore hand and arm function after chronic SCI, the Company anticipates an approximate list price of USD 30,000. Other ongoing studies include use of ARC-IM Therapy to address mobility after SCI and gait challenges in Parkinsons disease as well as using the ARC-BCI platform to restore thought-driven movement of both upper and lower limbs after SCI.Headquartered in Eindhoven, the Netherlands, ONWARD Medical has a Science and Engineering Center in Lausanne, Switzerland and a US office in Boston, Massachusetts.